Article
Variation in both IL28B and KIR2DS3 genes influence pegylated interferon and ribavirin hepatitis C treatment outcome in HIV-1 co-infection.
PloS one - 1 Jan 2013
Keane Ciara, O'Shea Daire, Reiberger Thomas, Peck-Radosavljevic Markus, Farrell Gillian, Bergin Colm, Gardiner Clair M
Abstract excerpt
Pegylated-IFN and ribavirin remains the current treatment for chronic HCV infection in patients co-infected with HIV-1, but this regimen has low efficacy rates, particularly for HCV genotype 1/4 infection, has severe side effects and is extremely costly. Therefore, accurate prediction of treatment response is urgently required. We have recently shown that the NK cell gene, KIR2DS3 and a SNP associated with the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.